Novel drugs targeting Toll-like receptors for antiviral therapy

Future Virology

Volumn 9, Issue 9, 2014, Pages 811-829

  Patel, Mira C ^a   Shirey, Kari Ann ^a   Pletneva, Lioubov M ^b   Boukhvalova, Marina S ^b   Garzino Demo, Alfredo ^a   Vogel, Stefanie N ^a   Blanco, Jorge C G ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Sigmovir Biosystems Inc ^*  (United States)

Author keywords

antiviral therapy; eritoran; innate immune system; monophosphoryl lipid A; poly ICLC; retrocyclin; TLR agonist; TLR antagonist; Toll like receptors; viruses

Indexed keywords

ANTIVIRUS AGENT; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 3 AGONIST; TOLL LIKE RECEPTOR 3 ANTAGONIST; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 4 AGONIST; TOLL LIKE RECEPTOR 4 ANTAGONIST; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 7 ANTAGONIST; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 8 AGONIST; TOLL LIKE RECEPTOR 8 ANTAGONIST; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; DRUG EFFICACY; DRUG TARGETING; GENE EXPRESSION; HUMAN; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SIGNAL TRANSDUCTION; TISSUE INJURY; VIRUS CELL INTERACTION; VIRUS INFECTION;

EID: 84908225462     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.14.70     Document Type: Article

References (172)

1. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34(5), 637-650 (2011).
2. Schenten D, Medzhitov R. The control of adaptive immune responses by the innate immune system. Adv. Immunol. 109, 87-124 (2011).
3. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology Cold Spring Har b. Symp. Quant. Biol. 54(Pt 1), 1-13 (1989).
4. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Dros op hi la adults. Cell 86(6), 973-983 (1996).
5. Poltorak A, He X, Smirnova I et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282(5396), 2085-2088 (1998).
6. Qureshi ST, Lariviere L, Leveque G et al. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J. Exp. Med. 189(4), 615-625 (1999).
7. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388(6640), 394-397 (1997).
8. O'neill LA, Bryant CE, Doyle SL. Therapeutic targeting of Toll-like receptors for infectious and infammatory diseases and cancer. Pharmacol. Rev. 61(2), 177-197 (2009).
9. Thompson MR, Kaminski JJ, Kurt-Jones EA, Fitzgerald KA. Pattern recognition receptors and the innate immune response to viral infection. Viruses 3(6), 920-940 (2011).
10. Roach JC, Glusman G, Rowen L et al. The evolution of vertebrate Toll-like receptors. Proc. Natl Acad. Sci. USA 102(27), 9577-9582 (2005).
11. Akira S, Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 4(7), 499-511 (2004).
12. Choe J, Kelker MS, Wilson IA. Crystal structure of human Toll-like receptor 3 (TLR3) ectodomain. Science 309(5734), 581-585 (2005).
13. Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem. Biophys. Res. Commun. 388(4), 621-625 (2009).
14. Andrade WA, Souza Mdo C, Ramos-Martinez E et al. Combined action of nucleic acid-sensing Toll-like receptors and TLR11/TLR12 heterodimers imparts resistance to Toxoplasma gondii in mice. Cell Host Microbe 13(1), 42-53 (2013).
15. Kurt-Jones EA, Popova L, Kwinn L et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol. 1(5), 398-401 (2000).
16. Rassa JC, Meyers JL, Zhang Y, Kudaravalli R, Ross SR. Murine retroviruses activate B cells via interaction with Toll-like receptor 4. Proc. Natl Acad. Sci. USA 99(4), 2281-2286 (2002).
17. Okumura A, Pitha PM, Yoshimura A, Harty RN. Interaction between Ebola virus glycoprotein and host Toll-like receptor 4 leads to induction of proinfammatory cytokines and SOCS1. J. Virol. 84(1), 27-33 (2010).
18. Imai Y, Kuba K, Neely GG et al. Identifcation of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury Cell 133(2), 235-249 (2008).
19. Lu B, Wang H, Andersson U, Tracey KJ. Regulation of HMGB1 release by infammasomes. Protein Cell 4(3), 163-167 (2013).
20. O'neill LA, Golenbock D, Bowie AG. The history of Toll-like receptors-redefning innate immunity. Nat. Rev. Immunol. 13(6), 453-460 (2013).
21. Zhang D, Zhang G, Hayden MS et al. A Toll-like receptor that prevents infection by uropathogenic bacteria. Science 303 (5663), 1522-1526 (2004).
22. Oldenburg M, Kruger A, Ferstl R et al. TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modifcation. Science 337(6098), 1111-1115 (2012).
23. Lien E, Chow JC, Hawkins LD et al. A novel synthetic acyclic lipid A-like agonist activates cells via the lipopolysaccharide/Toll-like receptor 4 signaling pathway. J. Biol. Chem. 276(3), 1873-1880 (2001).
24. Visintin A, Latz E, Monks BG, Espevik T, Golenbock DT. Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction. J. Biol. Chem. 278(48), 48313-48320 (2003).
25. Kim HM, Park BS, Kim JI et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist eritoran. Cell 130(5), 906-917 (2007).
26. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458(7242), 1191-1195 (2009).
27. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249(4975), 1431-1433 (1990).
28. Perera PY, Mayadas TN, Takeuchi O et al. CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and Taxol-inducible gene expression. J. Immunol. 166(1), 574-581 (2001).
29. Rallabhandi P, Phillips RL, Boukhvalova MS et al. Respiratory syncytial virus fusion protein-induced Toll-like receptor 4 (TLR4) signaling is inhibited by the TLR4 antagonists Rhodobacter sphaeroides lipopolysaccharide and eritoran (E5564) and requires direct interaction with MD-2. MBio 3(4), e00218-12 (2012).
30. Means TK, Lien E, Yoshimura A, Wang S, Golenbock DT, Fenton MJ. The CD14 ligands lipoarabinomannan and lipopolysaccharide differ in their requirement for Toll-like receptors. J. Immunol. 163 (12), 6748-6755 (1999).
31. Zanoni I, Ostuni R, Marek LR et al. CD14 controls the LPS-induced endocytosis of Toll-like receptor 4. Cell 147(4), 868-880 (2011).
32. O'Neill LA, Bowie AG. The family of fve: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol. 7(5), 353-364 (2007).
33. Bonham KS, Orzalli MH, Hayashi K et al. A promiscuous lipid-binding protein diversifes the subcellular sites of Toll-like receptor signal transduction. Cell 156(4), 705-716 (2014).
34. Carty M, Goodbody R, Schroder M, Stack J, Moynagh PN, Bowie AG. The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. Nat. Immunol. 7(10), 1074-1081 (2006).
35. Ni M, Macfarlane AWT, Toft M, Lowell CA, Campbell KS, Hamerman JA. B-cell adaptor for PI3K (BCAP) negatively regulates Toll-like receptor signaling through activation of PI3K. Proc. Natl Acad. Sci. USA 109(1), 267-272 (2012).
36. Troutman TD, Hu W, Fulenchek S et al. Role for B-cell adapter for PI3K (BCAP) as a signaling adapter linking Toll-like receptors (TLRs) to serine/threonine kinases PI3K/Akt. Proc. Natl Acad. Sci. USA 109(1), 273-278 (2012).
37. Moynagh PN. TLR signalling and activation of IRFs: revisiting old friends from the NF-kappaB pathway. Trends Immunol. 26(9), 469-476 (2005).
38. Honda K, Takaoka A, Taniguchi T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 25(3), 349-360 (2006).
39. Barton GM, Kagan JC. A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat. Rev. Immunol. 9(8), 535-542 (2009).
40. Bowie A, Kiss-Toth E, Symons JA, Smith GL, Dower SK, O'Neill LA. A46R and A52R from vaccinia virus are antagonists of host IL-1 and Toll-like receptor signaling. Proc. Natl Acad. Sci. USA 97(18), 10162-10167 (2000).
41. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413 (6857), 732-738 (2001).
42. Carty M, Bowie AG. Recent insights into the role of Toll-like receptors in viral infection. Clin. Exp. Immunol. 161(3), 397-406 (2010).
43. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol. 7(3), 179-190 (2007).
44. Bowie AG, Unterholzner L. Viral evasion and subversion of pattern-recognition receptor signalling. Nat. Rev. Immunol. 8(12), 911-922 (2008).
45. Lester SN, Li K. Toll-like receptors in antiviral innate immunity. J. Mol. Biol. 426(6), 1246-1264 (2014).
46. Lysakova-Devine T, Keogh B, Harrington B et al. Viral inhibitory peptide of TLR4, a peptide derived from vaccinia protein A46, specifcally inhibits TLR4 by directly targeting MyD88 adaptor-like and TRIF-related adaptor molecule. J. Immunol. 185 (7), 4261-4271 (2010).
47. Fekonja O, Avbelj M, Jerala R. Suppression of TLR signaling by targeting TIR domain-containing proteins. Curr. Protein Pept. Sci. 13(8), 776-788 (2012).
48. Bieback K, Lien E, Klagge IM et al. Hemagglutinin protein of wild-type measles virus activates Toll-like receptor 2 signaling. J. Virol. 76(17), 8729-8736 (2002).
49. Compton T, Kurt-Jones EA, Boehme KW et al. Human cytomegalovirus activates infammatory cytokine responses via CD14 and Toll-like receptor 2. J. Virol. 77(8), 4588-4596 (2003).
50. Dolganiuc A, Oak S, Kodys K et al. Hepatitis C core and nonstructural 3 proteins trigger Toll-like receptor 2-mediated pathways and infammatory activation. Gastroenterology 127(5), 1513-1524 (2004).
51. Ariza ME, Glaser R, Kaumaya PT, Jones C, Williams MV. The EBV-encoded dUTPase activates NF-kappa B through the TLR2 and MyD88-dependent signaling pathway. J. Immunol. 182(2), 851-859 (2009).
52. Leoni V, Gianni T, Salvioli S, Campadelli-Fiume G. Herpes simplex virus glycoproteins gH/gL and gB bind Toll-like receptor 2, and soluble gH/gL is suffcient to activate NF-kappaB. J. Virol. 86(12), 6555-6562 (2012).
53. Ge Y, Mansell A, Ussher JE et al. Rotavirus NSP4 triggers secretion of proinfammatory cytokines from macrophages via Toll-like receptor 2. J. Virol. 87(20), 11160-11167 (2013).
54. Murawski MR, Bowen GN, Cerny AM et al. Respiratory syncytial virus activates innate immunity through Toll-like receptor 2. J. Virol. 83(3), 1492-1500 (2009).
55. Szomolanyi-Tsuda E, Liang X, Welsh RM, Kurt-Jones EA, Finberg RW. Role for TLR2 in NK cell-mediated control of murine cytomegalovirus in vivo. J. Virol. 80(9), 4286-4291 (2006).
56. Zhu J, Martinez J, Huang X, Yang Y. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. Blood 109(2), 619-625 (2007).
57. Barbalat R, Lau L, Locksley RM, Barton GM. Toll-like receptor 2 on infammatory monocytes induces type I interferon in response to viral but not bacterial ligands. Nat. Immunol. 10(11), 1200-1207 (2009).
58. Sorensen LN, Reinert LS, Malmgaard L, Bartholdy C, Thomsen AR, Paludan SR. TLR2 and TLR9 synergistically control herpes simplex virus infection in the brain. J. Immunol. 181(12), 8604-8612 (2008).
59. Lima GK, Zolini GP, Mansur DS et al. Toll-like receptor (TLR) 2 and TLR9 expressed in trigeminal ganglia are critical to viral control during herpes simplex virus 1 infection. Am. J. Pathol. 177(5), 2433-2445 (2010).
60. Kurt-Jones EA, Chan M, Zhou S et al. Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc. Natl Acad. Sci. USA 101(5), 1315-1320 (2004).
61. Wang JP, Bowen GN, Zhou S et al. Role of specifc innate immune responses in herpes simplex virus infection of the central nervous system. J. Virol. 86(4), 2273-2281 (2012).
62. Dolganiuc A, Chang S, Kodys K et al. Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. J. Immunol. 177(10), 6758-6768 (2006).
63. Rose WA 2nd, McGowin CL, Pyles RB. FSL-1, a bacterial-derived Toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection. Virol. J. 6, 195 (2009).
64. Tabeta K, Georgel P, Janssen E et al. T o l l-l i k e receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc. Natl Acad. Sci. USA 101(10), 3516-3521 (2004).
65. Reinert LS, Harder L, Holm CK et al. TLR3 defciency renders astrocytes permissive to herpes simplex virus infection and facilitates establishment of CNS infection in mice. J. Clin. Invest. 122(4), 1368-1376 (2012).
66. Hardarson HS, Baker JS, Yang Z et al. Toll-like receptor 3 is an essential component of the innate stress response in virus-induced cardiac injury. Am. J. Physiol. Heart Circ. Physiol. 292(1), H251-258 (2007).
67. Richer MJ, Lavallee DJ, Shanina I, Horwitz MS. Toll-like receptor 3 signaling on macrophages is required for survival following coxsackievirus B4 infection. PLoS ONE 4(1), e4127 (2009).
68. Abe Y, Fujii K, Nagata N et al. The Toll-like receptor 3-mediated antiviral response is important for protection against poliovirus infection in poliovirus receptor transgenic mice. J. Virol. 86(1), 185-194 (2012).
69. Pott J, Stockinger S, Torow N et al. Age-dependent TLR3 expression of the intestinal epithelium contributes to rotavirus susc eptibi lit y. PLoS Pathog. 8(5), e1002670 (2012).
70. Zhang SY, Jouanguy E, Ugolini S et al. TLR3 defciency in patients with herpes simplex encephalitis. Science 317 (5844), 1522-1527 (2007).
71. Herman M, Ciancanelli M, Ou YH et al. Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood. J. Exp. Med. 209(9), 1567-1582 (2012).
72. Tsai YT, Chang SY, Lee CN, Kao CL. Human TLR3 recognizes dengue virus and modulates viral replication in vitro. Cell Microbiol. 11(4), 604-615 (2009).
73. Wang N, Liang Y, Devaraj S, Wang J, Lemon SM, Li K. Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells. J. Virol. 83(19), 9824-9834 (2009).
74. Handke W, Oelschlegel R, Franke R, Kruger DH, Rang A. Hantaan virus triggers TLR3-dependent innate immune responses. J. Immunol. 182(5), 2849-2858 (2009).
75. Gowen BB, Hoopes JD, Wong MH et al. TLR3 deletion limits mortality and disease severity due to Phlebovirus infection. J. Immunol. 177(9), 6301-6307 (2006).
76. Le Goffc R, Balloy V, Lagranderie M et al. Detrimental contribution of the Toll-like receptor (TLR)3 to infuenza A virus-induced acute pneumonia. PLoS Pathog. 2(6), e53 (2006).
77. Hutchens M, Luker KE, Sottile P et al. TLR3 increases disease morbidity and mortality from vaccinia infection. J. Immunol. 180(1), 483-491 (2008).
78. Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E, Flavell RA. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat. Med. 10 (12), 1366-1373 (2004).
79. Daffs S, Samuel MA, Suthar MS, Gale M Jr, Diamond MS. Toll-like receptor 3 has a protective role against West Nile virus infection. J. Virol. 82(21), 10349-10358 (2008).
80. Guillot L, Le Goffc R, Bloch S et al. Involvement of Toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and infuenza A virus. J. Biol. Chem. 280 (7), 5571-5580 (2005).
81. Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J. Virol. 79(11), 7269-7272 (2005).
82. Zhou Y, Wang X, Liu M et al. A critical function of Toll-like receptor-3 in the induction of anti-human immunodefciency virus activities in macrophages. Immunology 131(1), 40-49 (2010).
83. Mazaleuskaya L, Veltrop R, Ikpeze N, Martin-Garcia J, Navas-Martin S. Protective role of Toll-like receptor 3-induced type I interferon in murine coronavirus infection of macrophages. Viruses 4 (5), 901-923 (2012).
84. Zhao J, Wohlford-Lenane C, Zhao J et al. Intranasal treatment with poly(I:C) protects aged mice from lethal respiratory virus infections. J. Virol. 86 (21), 11416-11424 (2012).
85. Kato H, Takeuchi O, Mikamo-Satoh E et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J. Exp. Med. 205(7), 1601-1610 (2008).
86. Matsumoto M, Seya T. TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv. Drug Deliv. Rev. 60(7), 805-812 (2008).
87. Wang Y, Cella M, Gilfllan S, Colonna M. Cutting edge: polyinosinic:polycytidylic acid boosts the generation of memory CD8 T cells through melanoma differentiation-associated protein 5 expressed in stromal cells. J. Immunol. 184(6), 2751-2755 (2010).
88. Gowen BB, Wong MH, Jung KH et al. TLR3 is essential for the induction of protective immunity against Punta Toro virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not poly(I:C): differential recognition of synthetic dsRNA molecules. J. Immunol. 178(8), 5200-5208 (2007).
89. Wong JP, Christopher ME, Viswanathan S et al. Antiviral role of Toll-like receptor-3 agonists against seasonal and avian infuenza viruses. Curr. Pharm. Des. 15(11), 1269-1274 (2009).
90. Boukhvalova MS, Sotomayor TB, Point RC, Pletneva LM, Prince GA, Blanco JC. Activation of interferon response through Toll-like receptor 3 impacts viral pathogenesis and pulmonary Toll-like receptor expression during respiratory syncytial virus and infuenza infections in the cotton rat Sigmodon hispidus model. J. Interferon Cytokine Res. 30(4), 229-242 (2010).
91. Caskey M, Lefebvre F, Filali-Mouhim A et al. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J. Exp. Med. 208(12), 2357-2366 (2011).
92. Shen E, Li L, Li L et al. PIKA as an adjuvant enhances specifc humoral and cellular immune responses following the vaccination of mice with HBsAg plus PIKA. Cell. Mol. Immunol. 4(2), 113-120 (2007).
93. Lau YF, Tang LH, Ooi EE. A TLR3 ligand that exhibits potent inhibition of infuenza virus replication and has strong adjuvant activity has the potential for dual applications in an infuenza pandemic. Vaccine 27(9), 1354-1364 (2009).
94. Ranjith-Kumar CT, Duffy KE, Jordan JL et al. Single-stranded oligonucleotides can inhibit cytokine production induced by human Toll-like receptor 3. Mol. Cell. Biol. 28(14), 4507-4519 (2008).
95. Skold AE, Hasan M, Vargas L et al. Single-stranded DNA oligonucleotides inhibit TLR3-mediated responses in human monocyte-derived dendritic cells and in vivo in cynomolgus macaques. Blood 120(4), 768-777 (2012).
96. Haynes LM, Moore DD, Kurt-Jones EA, Finberg RW, Anderson LJ, Tripp RA. Involvement of Toll-like receptor 4 in innate immunity to respiratory syncytial virus. J. Virol. 75(22), 10730-10737 (2001).
97. Georgel P, Jiang Z, Kunz S et al. Ve sicu la r stomatitis virus glycoprotein G activates a specifc antiviral Toll-like receptor 4-dependent pathway. Virology 362(2), 304-313 (2007).
98. Tal G, Mandelberg A, Dalal I et al. Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J. Infect. Dis. 189(11), 2057-2063 (2004).
99. Awomoyi AA, Rallabhandi P, Pollin TI et al. Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young children. J. Immunol. 179 (5), 3171-3177 (2007).
100. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol. Cell Biol. 82(5), 488-496 (2004).
101. Thoelen S, Van Damme P, Mathei C et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 16(7), 708-714 (1998).
102. Baldridge JR, Mcgowan P, Evans JT et al. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin. Biol. Ther. 4 (7), 1129-1138 (2004).
103. Qureshi N, Takayama K, Ribi E. Purifcation and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium. J. Biol. Chem. 257(19), 11808-11815 (1982).
104. Evans JT, Cluff C W, Johnson DA, Lacy MJ, Persing DH, Baldridge JR. Enhancement of antigen-specifc immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev. Vaccines 2(2), 219-229 (2003).
105. Okemoto K, Kawasaki K, Hanada K, Miura M, Nishijima M. A potent adjuvant monophosphoryl lipid A triggers various immune responses, but not secretion of IL-1beta or activation of caspase-1. J. Immunol. 176(2), 1203-1208 (2006).
106. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316(5831), 1628-1632 (2007).
107. Didierlaurent AM, Morel S, Lockman L et al. AS04, an aluminum salt-and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity J. Immunol. 183(10), 6186-6197 (2009).
108. Rappuoli R, Mandl CW, Black S, De Gregorio E. Vaccines for the twenty-frst century society Nat. Rev. Immunol. 11(12), 865-872 (2011).
109. Steinhagen F, Kinjo T, Bode C, Klinman DM. TLR-based immune adjuvants. Vaccine 29(17), 3341-3355 (2011).
110. Garcon N, Van Mechelen M. Recent clinical experience with vaccines using MPL-and QS-21-containing adjuvant systems. Expert Rev. Vaccines 10(4), 471-486 (2011).
111. Schmidt AC, Johnson TR, Openshaw PJ et al. Respiratory syncytial virus and other pneumoviruses: a review of the international symposium-RSV 2003. Virus Res. 106(1), 1-13 (2004).
112. Blanco JC, Boukhvalova MS, Shirey KA, Prince GA, Vogel SN. New insights for development of a safe and protective RSV vaccine. Hum. Vaccin. 6(6), 482-492 (2010).
113. Prince GA, Jenson AB, Hemming VG et al Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J. Virol. 57(3), 721-728 (1986).
114. Prince GA, Curtis SJ, Yim KC, Porter DD. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J. Gen. Virol. 82(Pt 12), 2881-2888 (2001).
115. Prince GA, Denamur F, Deschamps M et al. Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease. Vaccine 19(15-16), 2048-2054 (2001).
116. Boukhvalova MS, Prince GA, Soroush L, Harrigan DC, Vogel SN, Blanco JC. The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease. Vaccine 24(23), 5027-5035 (2006).
117. Kamphuis T, Shafque M, Meijerhof T, Stegmann T, Wilschut J, De Haan A. Effcacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats. Vaccine 31(17), 2169-2176 (2013).
118. Blanco JC, Boukhvalova MS, Pletneva LM, Shirey KA, Vogel SN. A recombinant anchorless respiratory syncytial virus (RSV) fusion (F) protein/monophosphoryl lipid A (MPL) vaccine protects against RSV-induced replication and lung pathology. Vaccine 32(13), 1495-1500 (2014).
119. Christ WJ, Asano O, Robidoux AL et al. E5531, a pure endotoxin antagonist of high potency. Science 268(5207), 80-83 (1995).
120. Qureshi N, Takayama K, Kurtz R. Diphosphoryl lipid A obtained from the nontoxic lipopolysaccharide of Rhodopseudomonas sphaeroides is an endotoxin antagonist in mice. Infect. Immun. 59(1), 441-444 (1991).
121. Mullarkey M, Rose JR, Bristol J et al Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J. Pharmacol. Exp. Ther. 304(3), 1093-1102 (2003).
122. Opal SM, Laterre PF, Francois B et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 309(11), 1154-1162 (2013).
123. Nhu QM, Shirey K, Teijaro JR et al. Novel signaling interactions between proteinase-activated receptor 2 and Toll-like receptors in vitro and in vivo. Mucosal Immunol. 3(1), 29-39 (2010).
124. Shirey KA, Lai W, Scott AJ et al. The TLR4 antagonist eritoran protects mice from lethal infuenza infection. Nature 497(7450), 498-502 (2013).
125. Schaal JB, Tran D, Tran P et al. Rhesus macaque theta defensins suppress infammatory cytokines and enhance survival in mouse models of bacteremic sepsis. PLoS ONE 7(12), e51337 (2012).
126. Lehrer RI, Cole AM, Selsted ME. theta-defensins: cyclic peptides with endless potential. J. Biol. Chem. 287(32), 27014-27019 (2012).
127. Tang YQ, Yuan J, Osapay G et al. A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated alpha-defensins. Science 286(5439), 498-502 (1999).
128. Kokryakov VN, Harwig SS, Panyutich EA et al. Protegrins: leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins. FEBS Lett. 327(2), 231-236 (1993).
129. Gorden KK, Qiu XX, Binsfeld CC, Vasilakos JP, Alkan SS. Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifers and polyT oligodeoxynucleotides. J. Immunol. 177(10), 6584-6587 (2006).
130. Martinez J, Huang X, Yang Y. Toll-like receptor 8-mediated activation of murine plasmacytoid dendritic cells by vaccinia viral DNA. Proc. Natl Acad. Sci. USA 107(14), 6442-6447 (2010).
131. Cervantes-Barragan L, Zust R, Weber F et al. Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon. Blood 109 (3), 1131-1137 (2007).
132. Takahashi K, Asabe S, Wieland S et al. Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. Proc. Natl Acad. Sci. USA 107(16), 7431-7436 (2010).
133. Davidson S, Kaiko G, Loh Z et al. Plasmacytoid dendritic cells promote host defense against acute pneumovirus infection via the TLR7-MyD88-dependent signaling pathway. J. Immunol. 186(10), 5938-5948 (2011).
134. Kane M, Case LK, Wang C, Yurkovetskiy L, Dikiy S, Golovkina TV. Innate immune sensing of retroviral infection via Toll-like receptor 7 occurs upon viral entry. Immunity 35(1), 135-145 (2011).
135. Town T, Bai F, Wang T et al. Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infltration and homing. Immunity 30(2), 242-253 (2009).
136. Welte T, Reagan K, Fang H et al. Toll-like receptor 7-induced immune response to cutaneous West Nile virus infection. J. Gen. Virol. 90(Pt 11), 2660-2668 (2009).
137. Meier A, Chang JJ, Chan ES et al. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat. Med. 15(8), 955-959 (2009).
138. Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD 88-dependent signaling pathway. Nat. Immunol. 3(2), 196-200 (2002).
139. Gorden KB, Gorski KS, Gibson SJ et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol. 174(3), 1259-1268 (2005).
140. Miller RL, Meng TC, Tomai MA. The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect. 21(2), 69-87 (2008).
141. Nian H, Geng WQ, Cui HL et al. R-848 triggers the expression of TLR7/8 and suppresses HIV replication in monocytes. BMC Infect. Dis. 12, 5 (2012).
142. Cardoso EC, Pereira NZ, Mitsunari GE et al. TLR7/TLR8 activation restores defective cytokine secretion by myeloid dendritic cells but not by plasmacytoid dendritic cells in HIV-infected pregnant women and newborns. PLoS ONE 8(6), e67036 (2013).
143. Tajuddin T, Ryan EJ, Norris S, Hegarty JE, O'farrelly C. Interferon-alpha suppressed granulocyte colony stimulating factor production is reversed by CL097, a TLR7/8 agonist. J. Gastroenterol. Hepatol. 25(12), 1883-1890 (2010).
144. Fidock MD, Souberbielle BE, Laxton C et al. The innate immune response, clinical outcomes, and ex vivo HCV antiviral effcacy of a TLR7 agonist (PF-4878691). Clin. Pharmacol. Ther. 89(6), 821-829 (2011).
145. Jones HM, Chan PL, Van Der Graaf PH, Webster R. Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis C. Br. J. Clin. Pharmacol. 73(1), 77-92 (2012).
146. Xiang AX, Webber SE, Kerr BM et al. Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine. Nucleosides Nucleotides Nucleic Acids 26(6-7), 635-640 (2007).
147. Bergmann JF, De Bruijne J, Hotho DM et al. Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. Aliment. Pharmacol. Ther. 34(4), 443-453 (2011).
148. Boonstra A, Liu BS, Groothuismink ZM et al. Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7. Antivir. Ther. 17(4), 657-667 (2012).
149. Isobe Y, Kurimoto A, Tobe M et al. Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers. J. Med. Chem. 49(6), 2088-2095 (2006).
150. Lanford RE, Guerra B, Chavez D et al. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 144 (7), 1508-1517, 1517.e1-e10 (2013).
151. Lopatin U, Wolfgang G, Tumas D et al. Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist. Antivir. Ther. 18 (3), 409-418 (2013).
152. Robbins M, Judge A, Liang L, McClintock K, Yaworski E, Maclachlan I. 2'-O-methyl-modifed RNAs act as TLR7 antagonists. Mol. Ther. 15 (9), 1663-1669 (2007).
153. Sioud M. Development of TLR7/8 small RNA antagonists. Methods Mol. Biol. 629, 387-394 (2010).
154. Kandimalla ER, Bhagat L, Wang D et al. Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9. Nucleic Acids Res. 41(6), 3947-3961 (2013).
155. Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A. Toll-like receptor 9-mediated recognition of herpes simplex virus-2 by plasmacytoid dendritic cells. J. Exp. Med. 198(3), 513-520 (2003).
156. Hochrein H, Schlatter B, O'Keeffe M et al. Herpes simplex virus type-1 induces IFN-alpha production via Toll-like receptor 9-dependent and-independent pathways. Proc. Natl Acad. Sci. USA 101(31), 11416-11421 (2004).
157. Krug A, French AR, Barchet W et al. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 21(1), 107-119 (2004).
158. Zhu J, Huang X, Yang Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and-independent pathways. J. Virol. 81(7), 3170-3180 (2007).
159. Samuelsson C, Hausmann J, Lauterbach H et al. Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J. Clin. Invest. 118(5), 1776-1784 (2008).
160. Bochud PY, Hersberger M, Taffe P et al. Polymorphisms in Toll-like receptor 9 infuence the clinical course of HIV-1 infection. AIDS 21(4), 441-446 (2007).
161. Krieg AM. CpG still rocks! Update on an accidental drug. Nucleic Acid Ther. 22(2), 77-89 (2012).
162. Malaspina A, Moir S, Dipoto AC et al. CpG oligonucleotides enhance proliferative and effector responses of B cells in HIV-infected individuals. J. Immunol. 181(2), 1199-1206 (2008).
163. Vicari A P, Schmalbach T, Lekstrom-Himes J et al. Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic Toll-like receptor 9 agonist. Antivir. Ther. 12(5), 741-751 (2007).
164. McHutchison JG, Bacon BR, Gordon SC et al. Phase 1b, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 46(5), 1341-1349 (2007).
165. Kandimalla ER, Bhagat L, Zhu FG et al. A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specifc recognition observed with CpG motif. Proc. Natl Acad. Sci. USA 100(24), 14303-14308 (2003).
166. Kandimalla ER, Bhagat L, Li Y et al. Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent Toll-like receptor 9 agonists. Proc. Natl Acad. Sci. USA 102(19), 6925-6930 (2005).
167. Hutchens MA, Luker KE, Sonstein J, Nunez G, Curtis JL, Luker GD. Protective effect of Toll-like receptor 4 in pulmonary vaccinia infection. PLoS Pathog. 4(9), e1000153 (2008).
168. Zucchini N, Bessou G, Traub S et al. Cutting edge: overlapping functions of TLR7 and TLR9 for innate defense against a herpesvirus infection. J. Immunol. 180(9), 5799-5803 (2008).
169. Slater L, Bartlett NW, Haas JJ et al. Co-ordinated role of TLR3, RIG-I and MDA5 in the innate response to rhinovirus in bronchial epithelium. PLoS Pathog. 6(11), e1001178 (2010).
170. Rasmussen SB, Jensen SB, Nielsen C et al. Herpes simplex virus infection is sensed by both Toll-like receptors and retinoic acid-inducible gene-like receptors, which synergize to induce type I interferon production. J. Gen. Virol. 90(Pt 1), 74-78 (2009).
171. Guerrero-Plata A, Baron S, Poast JS, Adegboyega PA, Casola A, Garofalo RP. Activity and regulation of alpha interferon in respiratory syncytial virus and human metapneumovirus experimental infections. J. Virol. 79 (16), 10190-10199 (2005).
172. Krieg AM, Efer SM, Wittpoth M, Al Adhami MJ, Davis HL. Induction of systemic Th1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J. Immunother. 27(6), 460-471 (2004).